Author Archives: Lindsey Womack

The UNC Department of Neurology is proud to announce that Dr. Yael Shiloh‑Malawsky has been selected to receive the Excellence in Patient and Family Care Award from Carolina For The Kids Foundation, the largest student‑run nonprofit in North Carolina. Carolina For The Kids is dedicated to providing meaningful medical, emotional,...

David Y. Hwang, MD, FCCM, Professor of Neurology at the UNC School of Medicine, has been elected to a three-year term on the Board of Regents of the American College of Critical Care Medicine (ACCM). The ACCM Board of Regents provides strategic oversight and leadership for the College, which supports...

We are proud to announce that Dr. Daniel Roque has been promoted from Associate Professor to Professor in the Department of Neurology, effective February 1, 2026. Dr. Roque joined UNC Neurology in 2012 and has served as a Clinical Associate Professor since 2019. A nationally recognized movement disorders specialist, he...

Call for Abstracts Submission We welcome abstracts on all neurology-related research. Submissions should be concise and informative, limited to a single PDF page. The format is flexible, but the content must be clearly readable when printed on an A4 paper. Figures and tables are allowed as long as they fit within...

On September 20, 2025, patients, families, physicians, and experts gathered together for the First Carolinas Batten Diseases Family Day. What began as a collaborative effort among local families and the neurology teams at Duke and UNC evolved into a meaningful forum for shared knowledge, mutual support, and community building for...

UNC Research profiled Dr. Heidi Roth and her early love for creativity and human stories. As a behavioral neurologist at UNC, she focuses on personalized interventions, early diagnosis, and understanding sleep’s critical role in brain health and aging.

A groundbreaking clinical trial featured in Nature Medicine’s “Eleven Clinical Trials That Will Shape Medicine in 2026” is redefining the future of autoimmune disease treatment. The study, led by Dr. James Howard and Cartesian Therapeutics, explores the use of mRNA-based CAR T cell therapy for myasthenia gravis, a chronic autoimmune...

This study will gather information about patients who are taking new medicines for Alzheimer’s disease. We’ll keep an eye on how these patients are doing in the long run, tracking things like how they’re responding to treatment, what their overall health outcomes are like, and how safe these new treatments...

Brief Summary To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS) Detailed Description The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5...

A phase 3, open-label, single-arm, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity of Ravulizumab administered intravenously in pediatric participants (6 to <18 years of age) with generalized myasthenia gravis (gMG).